Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078338 · ClinicalTrials.gov registry record · Phase 4
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
A Phase 4 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 4
- Development phase
- 764
- Enrollment target
NCT00078338 is a Phase 4 study that has completed, run by EMD Serono. The registered enrollment target is 764 participants.
The verdict
NCT00078338, a Phase 4 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 764 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
Interventions
- DRUG Rebif®
- DRUG Copaxone®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 764 participants |
| Start Date | 2004-02-16 |
| Est. Completion | 2006-11-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00078338
The ClinicalTrials.gov registry entry for NCT00078338 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 764 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rebif® is the first listed.
NCT00078338 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00078338 about?
NCT00078338 is a clinical study titled "Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis". The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
What is the current status of trial NCT00078338?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 764 participants. The study started on 2004-02-16. Estimated completion is 2006-11-28.
What interventions are being tested in trial NCT00078338?
The interventions under investigation include: Rebif® (DRUG), Copaxone® (DRUG).
Who is sponsoring clinical trial NCT00078338?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.